Orrick Advises Tiziana on U.S. Follow-On Offering


Orrick’s Ed Lukins has advised biotech company Tiziana Life Sciences (NASDAQ: TLSA; AIM: TILS) on its U.S. follow-on offering of 3,333,333 of American Depositary Shares (ADS) on the NASDAQ Global Market. The ADSs priced at $3 per share, raising approximately $10 million. In addition, Tiziana has granted the underwriters a 45-day option to purchase up to an additional 500,000 ADSs. ThinkEquity, a division of Fordham Financial Management, Inc., acted as the sole book-running manager for the offering.